Clinical trials: Infection Viral
Hepatitis B
A Study of GSK3228836 in Participants With Chronic Hepatitis B (CHB)
Chronic hepatitis B virus (HBV) infection is a significant worldwide medical problem. GSK3228836 demonstrated target engagement in CHB participants who were not on treatment and in CHB participants on stable nucleos(t)ide…
- Trial name
- B-Clear (NCT04449029)
- Testing
- GSK3228836, Nucleos(t)ide therapy
- Where
- 121 sites in United States, Argentina and 20 more
- Volunteers
- 457 people
- Sponsor
- GlaxoSmithKline
Arbovirus Infections
The Interest of Systematic Screening for Dengue, Chikungunya, and Zika, in Malaria-negative Return Travelers
International travel has increased dramatically in recent years. Vector-borne pathologies such as malaria and arboviruses are common etiologies of post-travel fever, which are prevalent in similar geographical areas (tropical and…
- Trial name
- NCT06651372
- Testing
- The retrospective analyses planned for these samples consist of serological analysis and molecular analysis (RT-PCR ) according to the date of symptoms ons
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Strasbourg, France
Herpes Zoster
Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine GSK1437173A in Adults With a Prior Episode of Herpes Zoster
The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in subjects' ≥ 50 years of age (YOA) who previously have had Herpes Zoster (HZ).
- Trial name
- NCT01827839
- Testing
- Herpes Zoster vaccine (GSK1437173A)
- Where
- 4 sites in Canada, Russia
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Covid19
Decision Support System Algorithm for COVID-19 Diagnosis
COVID-19 is an infectious disease caused by a newly discovered Coronavirus which was first identified in Wuhan, China in December 2019.
- Trial name
- NCT04479319
- Testing
- Thorax CT
- Where
- 2 sites in Turkey (Türkiye)
- Volunteers
- 3,215 people
- Sponsor
- Ankara University
Chronic Hepatitis C
Peginterferon Alfa-2a and Ribavirin for Genotype 2 Chronic Hepatitis C: Duration and Ribavirin Dose Stratified by RVR
Treatment with peginterferon plus daily low dose (800 mg) or weight-based ribavirin (800-1400 mg) for 24 to 48 weeks has achieved 70-93% sustained virologic response (SVR) rates in patients with genotype 2 or 3 chronic hepatitis…
- Trial name
- NCT00532701
- Testing
- Peg-IFN + WB RBV for 16 weeks, Peg-IFN + LD RBV for 16 weeks, Peg-IFN + WB RBV for 24 weeks
- Where
- 9 sites in Taiwan
- Volunteers
- 880 people
- Sponsor
- National Taiwan University Hospital
Covid19
COVID-19 Saliva Test Research Study
The objective of this study is to compare the Chronomics test against the NPS tests and protocol currently in use to demonstrate the efficacy of Chronomics' approach.
- Trial name
- NCT04531501
- Testing
- Saliva and NPS test
- Where
- 2 sites in United Kingdom
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Chronomics Limited
Respiratory Syncytial Virus Infections
RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.
A total of 96 subjects will be recruited into 5 groups. Each subject will receive either two vaccinations with MVA-BN-RSV vaccine or placebo.
- Trial name
- NCT02864628
- Testing
- MVA-BN-RSV
- Volunteers
- healthy volunteers welcome
- Sponsor
- Bavarian Nordic
Hepatitis C
Ribavirin, Its Dosing Regime
The purpose of this study is to determine if the medicines for chronic hepatitis C can be taken once daily, instead of twice daily.
- Trial name
- Ribados (NCT00484328)
- Testing
- Ribavirin
- Where
- Netherlands
- Volunteers
- 15 people
- Sponsor
- Maastricht University Medical Center
Non-Hodgkin Lymphoma (NHL)
Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab
The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma.
- Trial name
- Rituxivac (NCT01707628)
- Testing
- influenza vaccination with influenza vaccine
- Where
- 7 sites in Netherlands
- Volunteers
- 98 people, healthy volunteers welcome
- Sponsor
- St. Antonius Hospital
Smoking Cessation
COVID-19 Brief Advice and Chat-based Support for Smoking Cessation Via "Quit to Win" Contest 2020
The present study will examine (1) the effectiveness of a combined brief advice and personalized chat-based support on COVID-19 related smoking messages and (2) explore the use of CBPR model to build capacity and to engage…
- Trial name
- QTW2020 (NCT04399967)
- Testing
- Chat-based support, AWARD plus COVID-specific advice, AWARD advice
- Where
- China
- Volunteers
- 1,166 people
- Sponsor
- The University of Hong Kong
Respiratory Syncytial Virus
A Study in Belgian Children Hospitalized With Respiratory Syncytial Virus Related Acute Respiratory Infections
The purpose of the study is to assess viral kinetics and clinical symptoms kinetics in pediatric patients hospitalized with Respiratory Syncytial Virus (RSV) confirmed lower respiratory tract infection (LRTI).
- Trial name
- NCT02133092
- Testing
- No intervention
- Where
- 4 sites in Belgium
- Volunteers
- 62 people
- Sponsor
- Janssen Research & Development, LLC
Hepatocellular Carcinoma
Immunotherapy of Advanced Hepatitis B Related Hepatocellular Carcinoma With γδT Cells
To evaluate the safety, tolerability and efficacy of autologous γδT cells in the treatment of advanced hepatitis B-related hepatocellular carcinoma.
- Trial name
- NCT04032392
- Testing
- autologous γδT cells
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Beijing 302 Hospital
HIV Infections, Acquired Immunodeficiency Syndrome
Vicriviroc in HIV-Treatment Experienced Subjects (Study P04405AM5)
Vicriviroc (vye-kri-VYE-rock) is an investigational drug (not yet approved by Government Regulatory Authorities for commercial use) that belongs to a new class of drugs, called CCR5 receptor blockers.
- Trial name
- NCT00523211
- Testing
- Vicriviroc
- Volunteers
- 506 people
- Sponsor
- Merck Sharp & Dohme LLC
Human Immunodeficiency Virus, Human Papilloma Virus
The Prevalence of Oral HPV Infection and Oral Lesions in People Living With HIV
The study will evaluate 300 people living with HIV that attend the Vivent Clinic for HIV care. We will characterize our population and include age, race/ethnicity, sex at birth, tobacco use, alcohol use, other comorbidities, HPV…
- Trial name
- SWISH (NCT06205511)
- Testing
- Oral HPV Sample
- Where
- 3 sites in United States
- Volunteers
- 300 people
- Sponsor
- Vivent Health
Hepatitis C, Medication Adherence
Directly Observed Hepatitis C Treatment in Methadone Clinics
Drug users account for a disproportionately large burden of hepatitis C virus (HCV) infection. However, HCV treatment adherence rates in drug users may be suboptimal in patients who use drugs regularly during HCV treatment.
- Trial name
- NCT01442311
- Testing
- enhanced DOT (both pegylated interferon alfa-2a and ribavirin), standard DOT (PEG-DOT control arm)
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Albert Einstein College of Medicine
Human Immunodeficiency Virus, Tuberculosis
Usability Study of IeHS in Indonesia
Technology that has a particular focus on patients' needs and ease-of-use and -access plays a significant role in the development of e-health and m-health.
- Conditions
- Human Immunodeficiency Virus, Tuberculosis, Interpersonal Relations, Mobile Phone Use
- Trial name
- NCT04179344
- Testing
- Integrated e-healthcare services (IeHS) web-based app
- Where
- 3 sites in Indonesia
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Bekasi City Public Hospital
Substance Abuse, Intimate Partner Violence (IPV)
SER Familia: A Family-Based Intervention Addressing Syndemic Conditions Among Latino Families
This study aims to prevent syndemic health conditions by decreasing acculturative stress and promoting resilience via SER Familia (Salud, Estrés y Resilencia en Familias/ Health, Stress, and Resilience in Families), a…
- Conditions
- Substance Abuse, Intimate Partner Violence (IPV), HIV Infections, Depression
- Trial name
- SER Familia (NCT06627764)
- Testing
- SER Familia
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Duke University
Dengue Fever
Impact of SC vs IM Administration of DENVax (TDV) on Safety and Immunogenicity
This study assessed the safety and immunogenicity of Takeda's Tetravalent Dengue Vaccine Candidate (TDV) previously referred to as DENVax of various dosing schedules via subcutaneous (SC) or intramuscular (IM) administration with…
- Trial name
- NCT01728792
- Testing
- TDV
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Takeda
COVID-19
Study on the Safety and Efficacy of Meplazumab for Injection Patients COVID-19
This is a multicenter, randomized, double-blind, placebo-controlled, add-on Phase III clinical study. Based on the "Diagnosis and Treatment Protocol for COVID-19 Pneumonia (Trial 10th edition)" and according to the results of…
- Trial name
- NCT05679492
- Testing
- Meplazumab foe injection, Normal saline
- Where
- China
- Sponsor
- Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd
HIV Infections
Safety of and Immune Response to a New HIV Vaccine: HIV CTL MEP
The effectiveness of a vaccine can be improved by using a "prime boost strategy" or by using an adjuvant. A prime boost strategy is the administration of one type of vaccine (the primer) followed by the administration of another…
- Trial name
- NCT00076037
- Testing
- HIV CTL MEP administered with RC529-SE adjuvant, GM-CSF
- Where
- 7 sites in United States
- Volunteers
- 96 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.